Lys88
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys88  -  MTHFD2 (human)

Site Information
SHSYVLNkTRAAAVV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1876877400

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , HCT116 (intestinal) ( 1 ) , HeLa (cervical) ( 1 )

Upstream Regulation
Treatments:
cisplatin ( 1 )

Downstream Regulation
Effects of modification on MTHFD2:
enzymatic activity, inhibited ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal cancer ( 1 )

References 

1

Wan X, et al. (2020) Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell. Cell Death Dis 11, 649
32811824   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.